# Guardant Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/guardant-health

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.guardanthealth.com/
- Total disclosed funding: $500M
- Latest round: Series E (May 9, 2017)
- Investors on record: 16

## About

Guardant Health, Inc. is a US-based biotechnology company specializing in innovative blood-based tests aimed at improving cancer detection and treatment through advanced genomic analysis.Founded in 2012 in Palo Alto, US, Guardant Health, Inc. focuses on precision oncology via non-invasive tests. The company successfully raised USD 350 mn in a Private Placement/Follow on round on May 22, 2023, matching their total raised amount of USD 350 mn. Jay Shendure is one of the key figures behind the company, contributing to its foundation and strategic direction.Guardant Health's primary offerings include blood-based tests designed for cancer detection and treatment. Their flagship product, the Shield™ Blood Test, provides a non-invasive method for colorectal cancer screening by analyzing circulating tumor DNA. They also offer Guardant Complete® and Guardant Infinity™, which support advanced cancer treatment and monitoring. The company's clientele consists of hospitals, oncologists, and healthcare providers across the US, Europe, and select Asian markets, all focused on enhancing patient care through precision oncology.In the most recent year, 2024, Guardant Health reported a revenue of USD 739.02 mn, with an EBITDA of USD -401.21 mn. The company generates revenue by selling its proprietary blood tests and associated services to healthcare providers, facilitating a straightforward purchasing process based on transaction needs.Guardant Health plans to utilize the recent funding of USD 350 mn primarily to expand its Project LUNAR early cancer detection program. The company is also focused on launching new product offerings and expanding into emerging markets by 2025. These initiatives are aimed at enhancing their product line and reaching new geographical regions as part of their strategic growth.

## Funding rounds

- Series E, May 9, 2017, $320M — Lightspeed Venture Partners, OrbiMed Advisors, Hong Shan, T Rowe Price, Temasek Holdings, Khosla Ventures, C.M. Capital Advisors, SoftBank Group, 8VC, SB Investment Advisers
- Series D, Dec 21, 2015, $83M — Lightspeed Venture Partners, OrbiMed Advisors, Hong Shan, Khosla Ventures, Felicis Ventures, Formation8, Pear VC, Heritage Group, Hone Capital
- Series C, Dec 16, 2014, $56M — Lightspeed Venture Partners, Hong Shan, Khosla Ventures, Formation8
- Series B, Apr 11, 2014, $32M — Hong Shan, Khosla Ventures, Pear VC
- Series A, Apr 22, 2013, $9.2M — Hong Shan, OUP (Osage University Partners)

## Investors

- Hong Shan — Series A, Series B, Series C, Series D, Series E
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A
- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series B, Series C, Series D, Series E
- Pear VC (https://capitalatlas.ai/funds/pear-vc) — Series B, Series D
- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series C, Series D, Series E
- Formation8 (https://capitalatlas.ai/funds/formation8) — Series C, Series D
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series D, Series E
- Felicis Ventures (https://capitalatlas.ai/funds/felicis-ventures) — Series D
- Heritage Group — Series D
- Hone Capital — Series D
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series E
- Temasek Holdings — Series E
- C.M. Capital Advisors — Series E
- SoftBank Group — Series E
- 8VC (https://capitalatlas.ai/funds/8vc) — Series E
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series E